Abstract:Individuals with naturally occurring loss-of-function PCSK9, APOC3, and ANGPTL3 mutations experience reduced blood low-density lipoprotein cholesterol (LDL-C) levels, reduced blood triglyceride levels, and/or protection against cardiovascular disease. We recently established that genome editing using a Streptococcus pyogenes clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) system, delivered by adenovirus, can efficiently introduce loss-of-function mutations into the endogenous mouse Pcsk9 gene in vivo, resulting in near-complete knockout of Pcsk9 and a 35%-40% reduction in the blood cholesterol level. Thus, the in vivo genome-editing approach may have therapeutic potential for the prevention of cardiovascular disease in humans. To better evaluate the feasibility of the approach in humans, we are performing preclinical studies using a liver-humanized mouse model in which the endogenous mouse hepatocytes have been replaced with human-derived hepatocytes and in which the plasma lipoprotein profile better reflects human physiology, particularly with respect to LDL-C. One disadvantage of the S. pyogenes CRISPR-Cas9 system is that its Cas9 gene is too large to fit in adeno-associated virus (AAV) vectors, which offer significant therapeutic advantages over adenoviruses. We have adapted the smaller Staphylococcus aureus CRISPR-Cas9 system and demonstrated efficient genome editing of the human PCSK9, APOC3, and ANGPTL3 genes in vitro. Additionally, using a minimal liver-specific promoter and a novel human-hepatocyte-optimized AAV capsid protein, we are employing AAV vectors to knock out each of the three genes in both primary human hepatocytes and liver-humanized mice. This is allowing us to interrogate both the efficacy (lowering of LDL-C and/or triglycerides) and safety (degree of off-target mutagenesis) of genome editing in human hepatocytes in vitro and in vivo. These translational studies are providing critical information on the viability of an approach that could ultimately yield a one-shot, long-term therapy that permanently reduces a person’s blood LDL-C and triglyceride levels, thus serving as a “vaccination” against cardiovascular disease.

In vivo prime editing of a metabolic liver disease in mice

Treatment of a genetic liver disease in mice through transient prime editor expression

Efficient prime editing in mouse brain, liver and heart with dual AAVs

Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

Prime editing for functional repair in patient-derived disease models

Evolution of Prime Editing Systems: Move Forward to the Treatment of Hereditary Diseases

Search-and-replace genome editing without double-strand breaks or donor DNA

Improved split prime editors enable efficient in vivo genome editing

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration

A robust and inducible precise genome editing via an all-in-one prime editor in human pluripotent stem cells

Prime Editing for Human Gene Therapy: Where Are We Now?

Deletion and replacement of long genomic sequences using prime editing

A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver

Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo

Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing

Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression

Improved nuclease-based prime editing by DNA repair modulation and pegRNA engineering

Abstract 27: Therapeutic Targeting of Human Lipid Genes With in vivo CRISPR-Cas9 Genome Editing

A prime editor mouse to model a broad spectrum of somatic mutations in vivo

CRISPR-Cas9 DNA Base-Editing and Prime-Editing